NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 294 filers reported holding NEKTAR THERAPEUTICS in Q3 2019. The put-call ratio across all filers is 0.81 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,089 | -11.3% | 3,506,681 | -14.3% | 0.00% | +33.3% |
| Q2 2023 | $2,354 | +11.5% | 4,091,681 | +36.2% | 0.00% | 0.0% |
| Q1 2023 | $2,111 | +696.6% | 3,003,696 | +2464.8% | 0.00% | – |
| Q4 2022 | $265 | -100.0% | 117,111 | -64.2% | 0.00% | -100.0% |
| Q2 2019 | $11,636,000 | +68.6% | 327,048 | +59.2% | 0.01% | +66.7% |
| Q1 2019 | $6,903,000 | -47.8% | 205,448 | -48.9% | 0.01% | -57.1% |
| Q4 2018 | $13,212,000 | +214.8% | 401,948 | +483.8% | 0.01% | +250.0% |
| Q3 2018 | $4,197,000 | +197.9% | 68,848 | +138.7% | 0.00% | +300.0% |
| Q2 2018 | $1,409,000 | -74.3% | 28,848 | -68.6% | 0.00% | -83.3% |
| Q4 2017 | $5,485,000 | -12.2% | 91,848 | -83.8% | 0.01% | -53.8% |
| Q1 2015 | $6,249,000 | -6.7% | 568,048 | +31.4% | 0.01% | -18.8% |
| Q4 2014 | $6,698,000 | – | 432,148 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |